DOI: 10.1002/1878-0261.13561 ISSN: 1574-7891

Preclinical evaluation of the gorilla‐derived HAdV‐B AdV‐lumc007 oncolytic adenovirus ‘GoraVir’ for the treatment of pancreatic ductal adenocarcinoma

Selas T.F. Bots, Tom J. Harryvan, Christianne Groeneveldt, Priscilla Kinderman, Vera Kemp, Nadine van Montfoort, Rob C. Hoeben
  • Cancer Research
  • Genetics
  • Molecular Medicine
  • General Medicine
  • Oncology

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy which shows unparalleled therapeutic resistance due to its genetic and cellular heterogeneity, dense stromal tissue, and immune‐suppressive tumor microenvironment. Oncolytic virotherapy has emerged as a new treatment modality which uses tumor‐specific viruses to eliminate cancerous cells. Non‐human primate adenoviruses of the human adenovirus B (HAdV‐B) species have demonstrated considerable lytic potential in human cancer cells as well as limited preexisting neutralizing immunity in humans. Previously, we have generated a new oncolytic derivative of the gorilla‐derived HAdV‐B AdV‐lumc007 named ‘GoraVir’. Here, we show that GoraVir displays oncolytic efficacy in pancreatic cancer cells and pancreatic‐cancer‐associated fibroblasts. Moreover, it retains its lytic potential in monoculture and co‐culture spheroids. In addition, we established the ubiquitously expressed complement receptor CD46 as the main entry receptor for GoraVir. Finally, a single intratumoral dose of GoraVir was shown to delay tumor growth in a BxPC‐3 xenograft model at 10 days post‐treatment. Collectively, these data demonstrate that the new gorilla‐derived oncolytic adenovirus is a potent oncolytic vector candidate that targets both pancreatic cancer cells and tumor‐adjacent stroma.

More from our Archive